LHI.F · Living Cell Technologies Limited

-

Please sign in to comment on LHI.F

1 Comment

Admin

4 years, 1 month ago

Living Cell Technologies Limited is currently in a long term downtrend where the price is trading 43.1% below its 200 day moving average.

From a valuation standpoint, the stock is 59.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2091.6.

Finally, its free cash flow grew by 74.6% to $-313K since the same quarter in the previous year.

Based on the above factors, Living Cell Technologies Limited gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	AU000000LCT6
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	0.48
Market Cap	14M

ABOUT

Living Cell Technologies Limited

Algorae Pharmaceuticals Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.

LHI.F · Living Cell Technologies Limited

-

Living Cell Technologies Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Living Cell Technologies Limited using a moving average strategy